Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
68.11
-0.25 (-0.37%)
At close: Mar 3, 2026, 4:00 PM EST
68.70
+0.59 (0.87%)
After-hours: Mar 3, 2026, 7:35 PM EST
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,026,230
Profits / Employee
-$1,979,279
Market Cap
1.91B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | 718 | -5 | -0.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 800 |
| Ocular Therapeutix | 325 |
| Nuvation Bio | 291 |
| Syndax Pharmaceuticals | 270 |
| Relay Therapeutics | 188 |
| Celldex Therapeutics | 186 |
| Soleno Therapeutics | 152 |
| Aurinia Pharmaceuticals | 130 |
NKTR News
- 5 days ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets - PRNewsWire
- 7 days ago - Nektar Therapeutics to Participate in Two Investor Conferences in March - PRNewsWire
- 13 days ago - Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy - Seeking Alpha
- 14 days ago - Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis - PRNewsWire
- 18 days ago - Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 18 days ago - Can NKTR Stock Sustain Its 1,000% Rally? - Forbes
- 20 days ago - Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering - PRNewsWire
- 20 days ago - Why Is Nektar Therapeutics Stock Gaining Wednesday? - Benzinga